skip to main content

Xerostomia — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardHead & Neck CancerXerostomiaSCE Medical Oncology

A fit adult has untreated, slowly progressive, unresectable recurrent oropharyngeal squamous-cell carcinoma. PD-L1 combined positive score is 5, disease burden is low and there is no need for rapid cytoreduction. Which NICE-recommended first-line option most specifically fits?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Pembrolizumab monotherapy with the two-year treatment stopping rule

Explanation lettering: B = shown as A · A = shown as B

D is correct: TA661 recommends pembrolizumab monotherapy for CPS at least 1 with a 2-year stopping rule. A is a different regimen and, for cetuximab combination treatment, tumour-site restrictions matter; B is not the TA661 funded combination; C applies after platinum progression within a separate pathway; E is a chemotherapy option rather than the biomarker-selected first-line choice.

Reference: NICE TA661 pembrolizumab for untreated recurrent or metastatic HNSCC (Published 25 November 2020): https://www.nice.org.uk/guidance/ta661/chapter/1-Recommendations